CPX101

CPX101 is an investigational drug being developed primarily for the treatment of obesity. It is a dual-acting agent that functions as a glucagon-like peptide 1 receptor (GLP-1R) agonist and a gastric inhibitory polypeptide receptor (GIPR) antagonist. This mechanism aims to regulate glucose metabolism and promote weight loss by enhancing insulin secretion while reducing appetite and caloric intake. Clinical trials are ongoing to evaluate its efficacy, safety, pharmacokinetics, and immunogenicity in overweight or obese individuals without diabetes mellitus. The drug is administered via subcutaneous injection at varying doses in clinical studies[1][2][3][5][6].